BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20635329)

  • 1. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome.
    Chigrinova E; Mian M; Scandurra M; Greiner TC; Chan WC; Vose JM; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Tucci A; Facchetti F; Lazure T; Lambotte O; Montes-Moreno S; Piris MA; Nomdedeu JF; Uccella S; Rancoita PM; Kwee I; Zucca E; Bertoni F
    Hematol Oncol; 2011 Mar; 29(1):38-41. PubMed ID: 20635329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.
    Campbell J; Seymour JF; Matthews J; Wolf M; Stone J; Juneja S
    Eur J Haematol; 2006 Jun; 76(6):473-80. PubMed ID: 16529599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study.
    Talaulikar D; Dahlstrom JE; Shadbolt B; McNiven M; Broomfield A; Pidcock M
    Pathology; 2007 Dec; 39(6):580-5. PubMed ID: 18027262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometry in the bone marrow evaluation of follicular and diffuse large B-cell lymphomas.
    Palacio C; Acebedo G; Navarrete M; Ruiz-Marcellán C; Sanchez C; Blanco A; López A
    Haematologica; 2001 Sep; 86(9):934-40. PubMed ID: 11532621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement.
    Lee KW; Yi J; Choi IS; Kim JH; Bang SM; Kim DW; Im SA; Kim TY; Yoon SS; Lee JS; Bang YJ; Park S; Kim BK; Cho HI; Heo DS
    Ann Hematol; 2009 Sep; 88(9):829-38. PubMed ID: 19172274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of molecular staging by PCR-amplification of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma (DLBCL).
    Mitterbauer-Hohendanner G; Mannhalter C; Winkler K; Mitterbauer M; Skrabs C; Chott A; Simonitsch-Klupp I; Gleiss A; Lechner K; Jaeger U
    Leukemia; 2004 Jun; 18(6):1102-7. PubMed ID: 15085149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index.
    Chung R; Lai R; Wei P; Lee J; Hanson J; Belch AR; Turner AR; Reiman T
    Blood; 2007 Aug; 110(4):1278-82. PubMed ID: 17475910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
    Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
    Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective.
    Talaulikar D; Shadbolt B; Bell J; Khan K; Dahlstrom JE; McDonald A; Pidcock M; Broomfield A
    Histopathology; 2008 Feb; 52(3):340-7. PubMed ID: 18269585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.
    Yao Z; Deng L; Xu-Monette ZY; Manyam GC; Jain P; Tzankov A; Visco C; Bhagat G; Wang J; Dybkaer K; Tam W; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Møller MB; Winter JN; Piris MA; Fayad L; Liu Y; Song Y; Orlowski RZ; Kantarjian H; Medeiros LJ; Li Y; Cortes J; Young KH
    Leukemia; 2018 Feb; 32(2):353-363. PubMed ID: 28745330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Scandurra M; Mian M; Greiner TC; Rancoita PM; De Campos CP; Chan WC; Vose JM; Chigrinova E; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Montes-Moreno S; Piris MA; Facchetti F; Tucci A; Nomdedeu JF; Lazure T; Lambotte O; Uccella S; Pinotti G; Pruneri G; Martinelli G; Young KH; Tibiletti MG; Rinaldi A; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
    Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
    Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical significance in detection of immunoglobulin heavy chain clonal rearrangement in bone marrow of patients with B cell lymphoma].
    Chen ZY; Zhou XY; Zhang TM; Hong XN; Yin JL; Hu XC; Shi DR
    Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):183-8. PubMed ID: 19615255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature.
    Suguro M; Tagawa H; Kagami Y; Okamoto M; Ohshima K; Shiku H; Morishima Y; Nakamura S; Seto M
    Cancer Sci; 2006 Sep; 97(9):868-74. PubMed ID: 16856881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Significance of Bone Marrow Involvement as Confirmed by Bone Marrow Aspiration vs. Bone Marrow Biopsy in Diffuse Large B-cell Lymphoma.
    Hantaweepant C; Chinthammitr Y; Khuhapinant A; Sukpanichnant S
    J Med Assoc Thai; 2016 Mar; 99(3):262-9. PubMed ID: 27276736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffuse large B-cell lymphoma initially manifesting in the bone marrow.
    Kajiura D; Yamashita Y; Mori N
    Am J Clin Pathol; 2007 May; 127(5):762-9. PubMed ID: 17439835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characteristics and Prognostic Significance of Cytogenetic Abnormalities in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement].
    Liu W; Lyu R; Huang WY; Li CW; Liu H; Li J; Zou DH; Qiu LG; Yi SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):761-765. PubMed ID: 28641631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic value of a focal bone marrow lesion in diffuse large B-cell lymphosarcoma].
    Magomedova AU; Kremenetskaia AM; Vorob'ev IA; Kravchenko SK; Kaplanskaia IB; Samoĭlova RS; Gemdzhian EG; Vorob'ev AI
    Ter Arkh; 2004; 76(7):60-3. PubMed ID: 15379130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.